查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
醫生調查：醫生支持使用真實世界證據（RWE）指導治療
市場調查報告書
商品編碼
1764332

醫生調查：醫生支持使用真實世界證據（RWE）指導治療

Physician Poll: Doctors Back Real-World Evidence to Guide Care
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

醫生似乎普遍認可真實世界證據（RWE）在臨床指南和治療計劃中的價值。

監管機構、定價和償付機構以及製定臨床指南的組織可以使用 RWE（隨機對照試驗之外獲得的證據），但它如何影響執業醫生？

本調查詢問了法國、德國、義大利、西班牙、英國和美國的444位心臟科醫生、內分泌學家、神經學家、腫瘤學家和風濕病學家，詢問他們對 RWE 的了解和使用情況。

關鍵問題解答

  • 對 RWE 的了解程度如何？
  • RWE 應用於指導臨床指引。
  • RWE 應用於臨床決策支援工具。
  • RWE 在規劃病患治療方案方面有多大幫助？
  • 五年後，RWE 在規劃患者治療方案時將變得越來越重要。

方法論

檔案報告是基於自身的產業研究以及對產業意見領袖的深入訪談，並基於獨立、簡潔的分析而編寫。報告對製藥公司高管需要了解的關鍵發展和市場趨勢進行了詳細分析，以應對未來的機會和挑戰。每份報告的重點都基於對二手文獻的回顧和已發現的知識差距。基於這些初步研究，制定了基於證據、由專家指導的討論指南，以確保研究能夠解答最重要的問題。此外，採用嚴格的篩選標準，以確保受訪者擁有足夠的經驗、知識和地位來就此主題發表演講。

報告有何獨特之處？

FirstWordReports 是值得信賴的行業領導者，致力於製藥行業，為生物製藥專業人士和決策者提供深入、可操作的洞察。深厚的行業知識使能夠提供相關且有價值的洞察，幫助掌握新興趨勢，有效應對複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖（KOL）的獨立、公正的見解，報告能夠提供所需的準確性和可靠性。獨家訪談和資料，以及持續的市場監測，讓全面了解市場動態。報告涵蓋 40 多個活躍的疾病領域，包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售與行銷、市場准入和其他領域問題的看法，有助於做出更明智的資料驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

Doctors seem to widely recognise the value of real-world evidence (RWE) in clinical guidelines and treatment planning.

Regulators, pricing and reimbursement agencies, and organisations that produce clinical guidelines can draw on RWE - evidence generated outside of randomised controlled trials - but what impact is it having on practising physicians?

The poll asked 444 physicians from France, Germany, Italy, Spain, the UK and US who practise in cardiology, endocrinology, neurology, oncology and rheumatology about their knowledge and use of RWE.

Key Questions Answered:

  • How would you rate your knowledge of RWE?
  • How much do you agree or disagree with the following statement? ~RWE should be used to inform clinical guidelines.
  • How much do you agree or disagree with the following statement? ~RWE should be used to inform clinical decision-support tools.
  • How much value does RWE have for helping you to plan treatment programmes for your patients?
  • How much do you agree or disagree with the following statement? ~RWE will become increasingly important when planning treatment programmes for your patients in five years' time.

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?:

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.